Before any individual Ozempic lawsuits are prepared for trial, the court will address whether plaintiffs need specific testing results to establish they were diagnosed with gastroparesis.
MDL Court has rescheduled the Ozempic Science Day for September 4, after previously scheduled hearings were delayed when the federal judge presiding over the litigation passed away
Warning labels provided for users of the GLP-1 diabetes drug downplayed the risk of gastrointestinal side effects from Trulicity, lawsuit states.
Patients with eating disorders taking Wegovy and Zepbound may end up taking too much of the drugs, or experience other severe side effects.
Warning label failed to mention that symptoms of nausea and vomiting could be signs of gastroparesis from Ozempic, increasing the risk of severe injury.
While no data was available on why patients quit taking Ozempic and Wegovy, the drugs have been linked to reports of severe gastrointestinal side effects and stomach paralysis in some users.
Each plaintiff directly filing a new Ozempic lawsuit, Wegovy lawsuit or other claim over side effects of GLP-1 medication in the MDL will have 45 days to fill out the Plaintiff Fact Sheets, providing information about their injury and claim.
Regardless of which GLP-1 medication was taken for weight loss, researchers indicate users still reported significant rates of stomach paralysis, pancreatitis and gallbladder problems.
The risk of Ozempic and Wegovy vision changes were seven times higher than for patients who took non-semaglutide drugs for diabetes and weight loss.
Side effects of Farxiga and similar diabetes drugs have been linked to a number of potential health risks, including flesh-eating groin infections.
